Market Overview

UPDATE: Goldman Sachs Upgrades Quest Diagnostics to Buy on Improved Fundamentals

Share:
Related DGX
Fast Money Picks For July 28
Earnings Scheduled For July 23, 2015

In a report published Thursday, Goldman Sachs analyst Isaac Ro upgraded the rating on Quest Diagnostics (NYSE: DGX) from Neutral to Buy, and raised the price target from $56.00 to $67.00.

In the report, Ro noted, “We upgrade shares of DGX to Buy from Neutral and raise our 6-month price target to $67 (from $56), which implies 17% upside. After underperforming the S&P, HC peers, and direct comp LH over the past 12 months, we believe DGX is now poised for a turnaround and we see multiple catalysts to drive share outperformance.”

Quest Diagnostics closed on Wednesday at $57.30.

Latest Ratings for DGX

DateFirmActionFromTo
Jun 2015Goldman SachsDowngradesBuyNeutral
Jun 2015KeyBancInitiates Coverage onSector Weight
Mar 2015JMP SecuritiesInitiates Coverage onMarket Perform

View More Analyst Ratings for DGX
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Upgrades Analyst Ratings

 

Related Articles (DGX)

Get Benzinga's Newsletters